


en 1632

Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via First-Class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 6th day of August, 2003.

(s)


Linda S. Evans



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Lovenberg et al.	Atty. Docket:	ORT-1528
Serial No.:	09/993,159	Art Unit:	1632
Filed:	November 5, 2001	Examiner:	unknown
For:	Histamine Receptor H3 Modified Transgenic Mice		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Statement is supplemental to the Information Disclosure Statement dated February 4, 2002. Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 (or substitute form) citing references relating to the above-identified application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(b)(3). In the event that a first Office Action has been mailed, then this Statement is being filed under 37 C.F.R. § 1.97(c)(1) with the following statement as specified at 37 C.F.R. § 1.97(e). Each reference listed on the enclosed form was first cited in a counterpart international (PCT) application in a communication from the European Patent Office as International Searching Authority not more than three months prior to the filing of this Statement. A copy of the communication of the International Search Report (ISR), which is dated May 6, 2003, is enclosed.

A copy of each of the references listed on the enclosed form is enclosed. Each reference except for WO 03/004637 is in the English language. However, WO 00/31277 includes an English-language abstract and sequence listing.


This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that each cited reference qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information more material does not exist.

The Examiner is respectfully requested to initial the citations on the enclosed form to confirm consideration of each reference.

If any fees are due in connection with the filing of this Statement, please charge any necessary fees to Deposit Account No. 10-0750.

Respectfully submitted,

Date August 6, 2003


Linda S. Evans
Reg. No. 33,873

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 320-3406

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.